| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Carvedilol and traditional nonselective beta blockers for the secondary prophylaxis of variceal hemorrhage and portal hypertension related complications among patients with decompensated cirrhosis: a systematic review and network meta-analysis
|
Mingpun, Warunee
|
|
|
19 |
3 |
p. 647-661
|
artikel
|
| 2 |
Cell-free DNA methylation-based inflammation score as a marker for hepatocellular carcinoma among people living with HIV
|
Kim, Kyeezu
|
|
|
19 |
3 |
p. 596-606
|
artikel
|
| 3 |
Clinical characteristics and managements of congenital hepatic hemangioma: a cohort study of 211 cases
|
Gong, Xue
|
|
|
19 |
3 |
p. 682-691
|
artikel
|
| 4 |
Combination therapies with immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma with major vascular invasion
|
Kanda, Tatsuo
|
|
|
19 |
3 |
p. 487-489
|
artikel
|
| 5 |
Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium tumor thrombus
|
Zhong, Suixing
|
|
|
19 |
3 |
p. 560-575
|
artikel
|
| 6 |
Comment on: Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment
|
Uzair, Muhammad
|
|
|
19 |
3 |
p. 692-693
|
artikel
|
| 7 |
Estimates of the global prevalence of occult hepatitis B virus infection in population under 18 years old: a systematic review and meta-analysis
|
Pan, Yuchen
|
|
|
19 |
3 |
p. 493-506
|
artikel
|
| 8 |
Exercise and gender: what role play in living liver transplantation?
|
Yang, Hanwen
|
|
|
19 |
3 |
p. 695
|
artikel
|
| 9 |
Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis
|
Cheah, Mark C. C.
|
|
|
19 |
3 |
p. 607-618
|
artikel
|
| 10 |
Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, 1990–2021: a multi-model trend analysis and forecasting study
|
Yang, Ti
|
|
|
19 |
3 |
p. 619-632
|
artikel
|
| 11 |
Gut microbes associated with functional cure of chronic hepatitis B
|
Honda, Takashi
|
|
|
19 |
3 |
p. 519-528
|
artikel
|
| 12 |
How to explain the conflicting reports on all-cause mortality in the comparison of MASLD-only group with no-SLD group?
|
Hu, Yue
|
|
|
19 |
3 |
p. 694
|
artikel
|
| 13 |
Is it necessary to distinguish between combined hepatocellular carcinoma-cholangiocarcinoma with less than 10% of cholangiocarcinoma components versus hepatocellular carcinoma?
|
Zhou, Changwu
|
|
|
19 |
3 |
p. 576-585
|
artikel
|
| 14 |
Is it necessary to distinguish between combined hepatocellular carcinoma-cholangiocarcinoma with less than 10% of cholangiocarcinoma components versus hepatocellular carcinoma?
|
Paradis, V.
|
|
|
19 |
3 |
p. 490-492
|
artikel
|
| 15 |
Letter: Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial
|
Dalai, Motij Kumar
|
|
|
19 |
3 |
p. 696-697
|
artikel
|
| 16 |
Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment
|
Ding, Dawei
|
|
|
19 |
3 |
p. 673-681
|
artikel
|
| 17 |
Model of baseline clinicopathological features predicts non-resolution of drug-induced liver injury at 6 months
|
Bihari, Chhagan
|
|
|
19 |
3 |
p. 633-646
|
artikel
|
| 18 |
Non-canonical Wnt signaling pathway activated NFATC3 promotes GDF15 expression in MASH: prospective analyses of UK biobank proteomic data
|
Wang, Hao
|
|
|
19 |
3 |
p. 662-672
|
artikel
|
| 19 |
Regulatory role of gut microbiota in immunotherapy of hepatocellular carcinoma
|
Du, Jiajia
|
|
|
19 |
3 |
p. 507-518
|
artikel
|
| 20 |
Response to: Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial
|
Dalai, Motij Kumar
|
|
|
19 |
3 |
p. 698-699
|
artikel
|
| 21 |
Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial
|
Qin, Albert
|
|
|
19 |
3 |
p. 547-559
|
artikel
|
| 22 |
The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study
|
Hu, Li
|
|
|
19 |
3 |
p. 586-595
|
artikel
|
| 23 |
TRIM28 functions as SUMO ligase to SUMOylate TRAF6 and regulate NF-κB activation in HBV-replicating cells
|
Yang, Yanfang
|
|
|
19 |
3 |
p. 529-546
|
artikel
|
Tijdschrift beschrijving